Targeting intratumoral Tregs: The promise of CD25×TIGIT bispecific antibodies in solid tumor therapy.
作者信息
Venkatachalapathy Muthukumaran
机构信息
Department of Chemistry, Yale University, New Haven, CT, USA.
出版信息
Mol Ther. 2024 Nov 6;32(11):3758-3760. doi: 10.1016/j.ymthe.2024.10.013. Epub 2024 Oct 28.
Abstract
摘要
相似文献
1
Targeting intratumoral Tregs: The promise of CD25×TIGIT bispecific antibodies in solid tumor therapy.靶向肿瘤内调节性T细胞：CD25×TIGIT双特异性抗体在实体瘤治疗中的前景
Mol Ther. 2024 Nov 6;32(11):3758-3760. doi: 10.1016/j.ymthe.2024.10.013. Epub 2024 Oct 28.
2
A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion.一种 CD25×TIGIT 双特异性抗体通过选择性肿瘤内 Treg 细胞耗竭诱导抗肿瘤活性。
Mol Ther. 2024 Nov 6;32(11):4075-4094. doi: 10.1016/j.ymthe.2024.09.010. Epub 2024 Sep 7.
3
A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies.一种新型B7-H4xCD3双特异性T细胞衔接器（PF-07260437）与乳腺癌标准治疗和免疫检查点疗法协同作用。
Mol Cancer Ther. 2025 Jul 2;24(7):976-992. doi: 10.1158/1535-7163.MCT-24-0379.
4
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer.一种新型双特异性抗体药物偶联物，针对 HER2 和 HER3，对乳腺癌具有强大的治疗效果。
Acta Pharmacol Sin. 2024 Aug;45(8):1727-1739. doi: 10.1038/s41401-024-01279-8. Epub 2024 Apr 11.
5
PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors.PF-08046032：一种新型的、正在研究的靶向CD25的抗体药物偶联物，经优化可选择性清除晚期恶性肿瘤中的调节性T细胞。
Mol Cancer Ther. 2025 Jul 2;24(7):963-975. doi: 10.1158/1535-7163.MCT-25-0101.
6
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.通过靶向间皮素治疗实体瘤的 T 细胞导向抗体。
Acta Pharmacol Sin. 2024 Oct;45(10):2186-2198. doi: 10.1038/s41401-024-01316-6. Epub 2024 Jun 10.
7
Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA.新型抗人PD-1和VEGFA双特异性抗体JS207的表征及功能评估
Front Immunol. 2025 Jun 18;16:1612547. doi: 10.3389/fimmu.2025.1612547. eCollection 2025.
8
Bispecific Antibodies in Solid Tumors: Advances and Challenges.实体瘤中的双特异性抗体：进展与挑战
Int J Mol Sci. 2025 Jun 18;26(12):5838. doi: 10.3390/ijms26125838.
9
Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy.用双特异性抗体靶向单纯疱疹病毒糖蛋白D：通过寻找协同作用拓展治疗视野
Viruses. 2025 Feb 12;17(2):249. doi: 10.3390/v17020249.
10
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.一种靶向表达表皮生长因子受体（EGFR）实体瘤的CD16A双特异性天然细胞衔接器AFM24的首次人体I期研究。
Clin Cancer Res. 2025 Apr 1;31(7):1257-1267. doi: 10.1158/1078-0432.CCR-24-1991.
本文引用的文献
1
A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion.一种 CD25×TIGIT 双特异性抗体通过选择性肿瘤内 Treg 细胞耗竭诱导抗肿瘤活性。
Mol Ther. 2024 Nov 6;32(11):4075-4094. doi: 10.1016/j.ymthe.2024.09.010. Epub 2024 Sep 7.
2
The present and future of bispecific antibodies for cancer therapy.双特异性抗体在癌症治疗中的现在和未来。
Nat Rev Drug Discov. 2024 Apr;23(4):301-319. doi: 10.1038/s41573-024-00896-6. Epub 2024 Mar 6.
3
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.PD-L1 检查点阻断促进了调节性 T 细胞的活性，这是治疗抵抗的基础。
Sci Immunol. 2023 May 19;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173.
4
Antibody-based cancer immunotherapy by targeting regulatory T cells.通过靶向调节性T细胞的基于抗体的癌症免疫疗法。
Front Oncol. 2023 Apr 27;13:1157345. doi: 10.3389/fonc.2023.1157345. eCollection 2023.
5
Therapeutic targeting of regulatory T cells in cancer.癌症中调节性 T 细胞的治疗靶向。
Trends Cancer. 2022 Nov;8(11):944-961. doi: 10.1016/j.trecan.2022.06.008. Epub 2022 Jul 16.
6
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.肿瘤微环境中的调节性 T 细胞：新机制、潜在治疗策略和未来前景。
Mol Cancer. 2020 Jul 17;19(1):116. doi: 10.1186/s12943-020-01234-1.
7
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy.肿瘤微环境中的调节性T细胞与抗癌免疫治疗方法
Immune Netw. 2020 Feb 11;20(1):e4. doi: 10.4110/in.2020.20.e4. eCollection 2020 Feb.
8
Immune checkpoint inhibitors: recent progress and potential biomarkers.免疫检查点抑制剂：最新进展与潜在生物标志物。
Exp Mol Med. 2018 Dec 13;50(12):1-11. doi: 10.1038/s12276-018-0191-1.
9
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.抗 CTLA-4 免疫疗法不会耗尽人类癌症中的 FOXP3+调节性 T 细胞（Tregs）。
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.
10
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.瞬时调节性 T 细胞消融可阻止致癌基因驱动的乳腺癌并增强放疗。
J Exp Med. 2013 Oct 21;210(11):2435-66. doi: 10.1084/jem.20130762. Epub 2013 Oct 14.
Zotero 插件